1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sanjivani Paranteral Ltd.

Sanjivani Paranteral Ltd.

BBSE:SANJIVIN
152.80
INR
-7.60
(-4.74%)
6.22EPS
25.15P/E
1.90BMarket Cap
Sanjivani Paranteral Ltd.
BSE:SANJIVIN
(Bombay Stock Exchange)

Recent

price

152.80

P/E

ratio

25.15

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
244.9
254.36
257.2
268.31
225.1
195.51
54.59
30.24
41.3
27.15
29.07
30.38
35.25
45.95
59.19
55.95
62.23
Revenue per Share
3.75
4.56
4.12
2.7
-4.09
-24.82
-44.45
-89.95
-3.5
-2.9
1.67
4.85
4.51
5.28
6.89
5.56
6.15
Basic EPS, GAAP
-0.82
1.13
9.75
12.6
-2.64
-0.1
16.22
5.17
4.2
-0.3
0.17
7.84
3.59
-11.99
-15.27
-8.44
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.5
- -
Dividend per Share
48.17
52.53
56.65
59.35
54.5
29.67
-14.78
-89.55
-80.03
-82.93
-52.83
-7.58
-3.07
23.88
31.98
39.28
- -
Book Value per Share
48.17
52.53
56.65
59.35
54.5
29.67
-14.78
-89.55
-80.03
-82.93
-52.83
-7.58
-3.07
23.88
31.87
38
- -
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
6
8
10
10
12
12
12
12
Basic Weighted Avg Shares
1,445
1,500
1,518
1,583
1,328
1,153
322
178
244
160
247
304
352
537
696
683
746
Sales/Revenue/Turnover
6.7
7.02
6.7
5.64
2.94
-5.96
-47.43
-99.88
6.13
1.5
10.14
14.76
12.53
13.52
13.99
13.47
13.57
Operating Margin (%)
9
10
10
10
14
14
12
12
12
11
9
9
9
9
6
12
17
Depreciation Expense
22
27
24
16
-24
-146
-262
-531
-21
-17
14
48
45
62
81
68
74
Net Income, GAAP
37.38
17.69
35.95
47.49
- -
- -
- -
- -
- -
- -
- -
0.66
8.75
18.58
21.81
28.73
28.42
Effective Tax Rate (%)
1.53
1.79
1.6
1.01
-1.82
-12.7
-81.44
-297.44
-8.48
-10.67
5.74
15.95
12.8
11.48
11.64
9.94
9.89
Profit Margin (%)
221
171
161
158
231
86
-175
-632
-489
-516
-484
-142
-144
149
24
100
- -
Working Capital
91
97
68
55
48
124
70
45
81
80
53
27
8
10
53
86
- -
LT Debt
284
310
334
350
321
175
-87
-528
-472
-489
-449
-76
-31
279
399
508
- -
Total Equity
4.08
3.16
2.67
1.72
- -
- -
- -
- -
- -
- -
- -
308.08
370.53
38.67
19.65
11.23
- -
Return on Invested Capital (%)
4.08
11.07
7.84
5.84
- -
- -
- -
- -
- -
- -
- -
-2,309.63
-435.79
44.3
21.91
12.85
- -
Return on Capital (%)
7.84
9.06
7.55
4.66
-7.19
-58.98
- -
- -
- -
- -
- -
- -
- -
- -
24.58
15.74
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
57
- -
LT Borrowings
- -
86
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
2,844
1,631
1,900

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
364
- -
Cash, Cash Equivalents & STI
- -
13
- -
Accounts Receivable, Net
- -
154
- -
Inventories
- -
110
- -
Total Current Liabilities
- -
264
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
57
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-73.98%
-216.12%
27.51%
Free Cash Flow
-1,135.85%
922.18%
-42.61%
Net Income, GAAP
17.13%
57.27%
-16.2%
Sales/Revenue/Turnover
5.89%
23.8%
-1.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
164
181
173
182
696
2026
179
155
221
132
683
2027
238
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.47
1.96
1.62
1.84
6.89
2026
1.46
1.33
2.21
0.49
5.56
2027
2.03
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
0.5
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sanjivani Paranteral Ltd Sanjivani Paranteral Ltd (SANJIVIN.BO), founded in 1994 and headquartered in Mumbai, India, operates as a WHO-GMP certified pharmaceutical manufacturer specializing in research-based, export-oriented production of high-quality parenteral and oral solid formulations; its core products encompass small volume injectables, sterile powder formulations, tablets, capsules, ointments/creams, nutraceuticals, and branded generics across therapeutic areas including central nervous system, cardiovascular, antibiotics, gastroenterology, anti-diabetics, anti-allergics, urology, anesthetics, anti-fungals, anti-depressants, muscle relaxants, and vitamin supplements. The company maintains two primary manufacturing facilities in Mumbai (Navi Mumbai) and Dehradun, India, with exports accounting for over 80% of revenue to more than 25 countries in regions such as Africa, the Middle East, CIS countries, Europe, and Latin America; it also caters to domestic markets through collaborations with partners like Merind, Lupin Laboratories, USV, Cadila Ltd., Alkem Ltd., and Ranbaxy. Recent developments include a joint venture with Hindustan Antibiotics Limited to produce intravenous formulations and IV sets in Pune, Maharashtra, commencing commercial operations in September 2025 at an expected capacity of 5 million IV fluid bottles and 1 million IV sets per month; a partnership with Aievia Healthcare s.r.o. in Prague, Czech Republic, launched in 2023 for European Union market entry; incorporation of subsidiary SPL Infusion Private Limited in February 2024 with 60% ownership to support infusion production; plans for a new high-grade antibiotics and life-saving injectables plant in Taloja, Maharashtra; and ongoing product development in infusion injectables, IV sets, pre-filled syringes, oncology, and hormones, alongside capacity enhancements and regulatory upgrades.